Two-dimensional atom-and bond-based TOMOCOMD-CARDD descriptors and linear discriminant analysis (LDA) are used in this report to perform a quantitative structure-activity relationship (QSAR) study of tyrosinase-inhibitory activity. A database of inhibitors of the enzyme is collected for this study, within 246 highly dissimilar molecules presenting antityrosinase activity. In total, 7 discriminant functions are obtained by using the whole set of atom-and bond-based 2D indices. All the LDA-based QSAR models show accuracies above 90% in the training set and values of the Matthews correlation coefficient (C) varying from 0.85 to 0.90. The external validation set shows globally good classifications between 89% and 91% and C values ranging from 0.75 to 0.81. Finally, QSAR models are used in the selection/identification of the 20 new dicoumarins subset to search for tyrosinase inhibitory activity. Theoretical and experimental results show good correspondence between one another. It is important to remark that most compounds in this series exhibit a more potent inhibitory activity against the mushroom tyrosinase enzyme than the reference compound, Kojic acid (IC 50 = 16.67 μM), resulting in a novel nucleus base (lead) with antityrosinase activity, and this could serve as a starting point for the drug discovery of novel tyrosinase inhibitor lead compounds. (Journal of Biomolecular
INTRODUCTION
I n the past decades, the advantage brought by computational methods has increased the number of their applications in the domains of science. Chemistry is not exempt from this, and chemoinformatics, a multidisciplinary science, has emerged as a main tool related to this.1 Involving these aspects, the quantitative structure-activity relationship (QSAR) methods have numerous applications in drug discovery,2 making use of several molecular descriptor (MD) families and pattern recognition techniques. 1 The QSAR is the name usually applied to methods of this type that correlate the molecular structure with biological properties. The combination of these methods and others as highthroughput screening (HTS), in chemical data mining, can speed up the identification of optimal lead structures, 3 reducing the time in the drug discovery pipeline.
On the other hand, tyrosinase (EC 1.14.18.1) is an enzyme widely distributed in nature from microorganisms to human beings and responsible for many browning and pigmenting processes in nature. 4 In humans, it is associated with some hyperpigmentation disorders such as melasma, lentigo, and others. 5 Although some QSAR studies have been applied in studies of this enzyme and its inhibitors by using congeneric or heterogeneous data sets, 6, 7 the main studies about the discovery of tyrosinase inhibitor compounds have been made by using the traditional trial-and-error essays. 8 Taking into account the aspects above, a QSAR study of tyrosinase inhibitory activity is reported to obtain linear discriminant analysis (LDA) models that allow separating active from inactive compounds. A ligand-based virtual screening (LBVS) of drugs with other pharmacological uses was done. As a final point, the in silico and in vitro assays of a new family of compounds (dicoumarins) were carried out to show the reliability of the TOMOCOMD-CARDD method in the identification of new lead compounds, which can be used to look for new paradigms in the drug discovery process.
MATERIALS AND METHODS

Computational approach
The 2D MDs were generated by the interactive program for molecular design and bioinformatics research, TOMOCOMD. 9 It consists of 4 subprograms; every one of them allows both drawing the structures (drawing mode) and calculating molecular 2D/3D descriptors (calculation mode). The modules are named CARDD (Computed-Aided "Rational" Drug Design), CAMPS (Computed-Aided Modeling in Protein Science), CANAR (Computed-Aided Nucleic Acid Research), and CABPD (Computed-Aided Bio-Polymers Docking). The CARDD module was selected for drawing all structures and for the computation of TOMOCOMD MDs. The main steps for the application of this method in QSAR and drug design can be briefly summarized as follows. 1 . Drawing of the molecular pseudograph for every molecule in the data set, using the drawing mode. 2. Use of appropriate weights to differentiate between atoms in the molecule. The weights used in the present report are the ones previously proposed for the calculation of the DRAGON descriptors, [10] [11] [12] that is, atomic mass (M), atomic polarizability (P), atomic Mulliken electronegativity (K), van der Waals atomic volume (V), and the atomic electronegativity in the Pauling scale (G). 10-13 3. Computation of the total and local TOMOCOMD-CARDD fingerprints, which can be carried out in the software calculation mode, where one can select the atomic properties and the descriptor family before calculating the molecular indices. This software generates a table in which the rows correspond to the compounds and the columns correspond to the TOMOCOMD-CARDD (total and local) maps (linear, bilinear, and quadratic) of any family of MDs implemented in this program. 4. Development of a QSAR equation by using several multivariate analytical techniques, for instance, linear discrimination analysis. Therefore, one can find a quantitative relationship between an activity A and the fingerprints having, for example, the following appearance:
where A is the measured activity, X k (w) are the kth MDs, and the a k s and c are the coefficients obtained by the linear regression analysis. The robustness and predictive power of the QSPR/QSAR equation are tested by using external (using a test set as well as an external prediction set) validation techniques.
The MDs, calculated using the TOMOCOMD-CARDD software, were the atom-and bond-based quadratic, linear, and bilinear indices. Earlier publications outlined the theory of all these 2D TOMOCOMD-CARDD descriptors. 7, [14] [15] [16] [17] 
Data set exploration
Assembling any QSAR study requires a data set with a great molecular variability to ensure an adequate extrapolation power for the LDA models. This critical aspect is of major importance for the quality of the database. To this effect, we have selected 658 compounds for making up the data set, 246 with tyrosinase inhibitor activity, considering different modes of inhibition and structural diversity. Besides, the data set includes many different representative families, as well as the main tyrosinase inhibitor drugs used in therapeutics. In Table 1 (supplementary material), the names of compounds in the database are depicted, together with their experimental data taken from the literature. The molecular structures of these 246 tyrosinase inhibitors are given in Table 2 (supplementary material). This database could be considered a helpful tool for the scientist working in the area of tyrosinase inhibitors. The subset of 412 inactive compounds was chosen from chemicals with other pharmacological uses. 18
Statistical techniques
k-means cluster analysis (k-MCA). The statistical software package STATISTICA was used to develop k-MCA. 19 The number of members in each cluster and the standard deviation of the variables in the cluster (kept as low as possible) were taken into account to have an acceptable statistical quality of data partitions into clusters. The values of standard deviation (SS) between and within clusters, the respective Fisher ratio, and their p level of significance were also examined. 20 Finally, before carrying out the cluster processes, all variables were standardized. In standardization, all values of selected variables (molecular descriptors) were replaced by the standardized values.
Linear discriminant analysis. LDA was carried out with the STATISTICA software. 19 The considered tolerance parameter (the proportion of variance that is unique to the respective variable) was the default value for minimal acceptable tolerance, which is 0.01. A forward-stepwise search procedure was fixed as the strategy for variable selection. The principle of parsimony (Occam's razor) was taken into account as a strategy for model selection. In this connection, we selected the model with a high statistical significance but having as few parameters (a k ) as possible. The qualities of the models were determined by examining Wilks's λ parameter (U statistic), the square Mahalanobis distance (D 2 ), the Fisher ratio (F), and the corresponding p level (p(F)), as well as the percentages of good classification in the training and test sets. Models with a proportion lower than 5 between the number of cases and variables in the equation were rejected. The biological activity was coded by a binary (dummy) variable class. This dichotomic variable indicates the presence of either an active compound ((class) 1) or an inactive compound ((class) -1). The classification of cases was performed by the posterior classification probabilities. By using the models, one compound can then be classified as active, if ΔP% > 0 being ΔP% = [P(Active) -P(Inactive)]*100, or as inactive otherwise. P(Active) and P(Inactive) are the probabilities with which the equations classify a compound as active or inactive, respectively.
The statistical robustness and predictive power of the obtained model were proved using a prediction (test) set. Performing the assessment of the obtained models, the percentages of global good classification (accuracy), sensibility, specificity (also known as "hit rate"), false-positive rate (also known as "false alarm rate"), and the Matthews correlation coefficient (C) were calculated and checked in the training and test sets. 21 The canonical scores from the canonical correlation were obtained. These canonical scores are the values on a canonical variable for a given case, based on the canonical coefficients for that variable. Canonical coefficients are multiplied by the standardized scores of the cases and summed to yield the canonical scores for each case in the analysis.
Chemical methods and biochemical assays
The isolation, structural elucidation, and characterization of the compounds were reported in earlier publications by other members of our research teams. 22 
RESULTS AND DISCUSSION
Performing the data set selection
The structural diversity of the database is the first aspect that should be proved; following this aim, a hierarchical cluster analysis (CA) was carried out using the STATISTICA software. 19 All the variables showed p levels <0.05 for the Fisher test. Both independent partitional clusterings were developed for the active compounds first and for the inactive ones later. The inactive series, composed of drugs with different pharmacological activities, are compounds unproved in tyrosinase activity inhibition. The classification of these chemicals as "inactive" does not exclude that any inhibitory activity could exist for those compounds. This characteristic can be reflected in the results of classification for the series of inactive chemicals. 23 After that, a k-means cluster analysis (k-MCA) was done to ensure the correct selection of the variety of the different chemical families in both the training and prediction series. As can be observed in Figure 1 , the k-MCAs partitioned the set of tyrosinase inhibitors into 10 clusters for the active chemicals, and for the inactive ones (noninhibitors of tyrosinase), 12 clusters were obtained. Later, a random selection was carried out to extract a representative compound of every family inside each active and inactive cluster. In addition, to ensure a good splitting, we tried to satisfy that members of the validation set be closer at least to one point of the training set. This criterion, suggested in the international reports, was followed, permitting all subsystems to be represented simultaneously in the training and test sets. 24 To this effect, 478 compounds were chosen for the training set, which includes 183 and 295 active and inactive compounds, respectively. In the same way, for the validation of the QSAR model, the prediction series included the remaining 180 chemicals, with 63 of them being tyrosinase inhibitors and the rest 117 inactive compounds with other clinical uses. The described procedure to split the database into training and test sets for QSAR model construction is illustrated in Figure 1 .
LDA-QSAR models: construction and validation
After database selection, the next step consisted of assembling the models. Therefore, the LDA was chosen as a statistical technique because of its simplicity and wide application in chemometric studies. Seven LDA-QSAR models were obtained through the LDA module implemented in STATISTICA 6.0, 19 classifying the compounds as either active or inactive. These classification models are depicted in Table 1 .
In the case above, the atom-and bond-based TOMOCOMD-CARDD descriptors were used as independent variables. Statistical parameters and prediction results for these classification functions are given in Table 2 . The equations appeared statistically significant at p < 0.001. Models 2 to 4 were obtained using the atom-based indices and the rest (models 5-7) with the bond-based fingerprints of our in-house software. 25 As can be observed, the best result is shown by equation 8 ( Table 2) , resulting in the conjunction of all atom-and bond-based 2D descriptors implemented in the CARDD module of the TOMOCOMD software. This best model had a good overall accuracy of 95.40% in the training series. In addition, this equation showed an adequate Matthews correlation coefficient (C = 0.90), which gives a measure of prediction that is more balanced than other values such as accuracy. 26 Together with the accuracy, sensitivity, specificity, and false-positive rate (false alarm rate), some linear discriminant canonical statistics are depicted in the same table: canonical correlation coefficient (R can ) as well as chi-square (c 2 ) and its p level (p(χ 2 )). These results have adequate values in agreement with the results commonly expected with QSAR modeling of biological activities.
As has been stated by some authors, the validation process refers to a procedure in which the assessment of the obtained QSAR model is proved. Statistical external validation can be helpful to define more precisely the predictive power of the model. This is the best way of validation and the one recommended by some authors. 27, 28 In the statistical external validation, the predicted compounds are different from those included in the training set but representative of the chemical domain in the activity under study. Following this aim, our next step was to carry out the examination of the predictive power of our models through an external validation process. In this case, the quality of the fitted models was proved. The statistical parameters of the test set are depicted in Table 3 , showing good behavior in the values of accuracy, sensitivity, and specificity for all models. Equation 8 , the best model, shows an accuracy of 91.11% (C = 0.81) in the prediction series. The obtained acceptable values validate the models for their use in LBVS, taking into account the acceptable values of accuracy above 85% in the test set, which is considered a suitable threshold for this kind of analysis. 29 A plot of the ΔP% for the entire database using model (8) is shown in Figure 2 . In Tables 3 and 4 (supplementary material), the results of the classification (including canonical scores) for all the models in the training set are summarized. Furthermore, the complete classification results (ΔP%) and canonical scores, for the 7 LDA-QSAR models, in the whole test set (active and inactive compounds) are shown in Table 5 (supplementary material).
Another way of proving the robustness of the QSAR model is the Y-randomization test-in our case, a Y-random test for the best model (equation 8) was performed. In it, this model was compared with the ones obtained when a randomized activity of the training set was used. The training set was randomized in 5%, 10%, 15%, 20%, 25%, and 30% of the total (active and inactive) training set, and the values shown by these models were 90.37%, 85.15%, 81.38%, 76.77%, 71.13%, and 62.27% respectively. In Figure 3 , it is depicted by the plot of the accuracy versus Y-randomized percentage in every case. This result demonstrates that the global good classification values were not due to chance correlations or structural redundancy in the training set.
A ligand-based virtual screening to a small library of tyrosinase-inhibitors
The ligand-based methods are supported by the principle of similarity-similar compounds are assumed to produce similar effects; 30 they serve to model the complex phenomena of molecular recognition. Similarity-based methods are cornerstones of chemoinformatic and computer-aided pharmaceutical research. Therefore, LBVS has been used to identify novel active compounds in many biological applications. This indicates that "similarity" methods should have substantial "selectivity" in recognizing diverse active compounds. 31 The ability to identify novel active compounds needs to be assessed. Therefore, practical applications are as important as novel developments to advance the virtual screening field.
Therefore, taking into consideration the effectiveness demonstrated in the validation set by the QSAR models, a simulated LBVS was performed for a small database of 104 compounds, reported in the literature as active/inactive. The percentage of accuracy was of 90.38% for the data set, adequately classifying the active subset (91.76%) and inactive subset (84.10%) of these 104 compounds, compared with the recent reports in the literature (see Table 6 of supplementary material). Additionally, the molecular structures of the 104 organic-chemicals are depicted in Table 7 (supplementary material). The results of ΔP% (posterior classification probabilities) and canonical scores are also given in Table 8 of supplementary material.
The result above validates the use of ligand-based virtual screening methods for the new challenges to the field of marketable drug rediscovery processes. These methods are able to detect the presence of activity from a series of diverse drugs. New bioactive chemicals selected by this approach could shorten the identification from a large chemical library because these kinds of compounds have well-established methods of synthesis and ADMET predictions.
Detecting novel tyrosinase inhibitors through in silico and in vitro assays
Current purposes of integrating chemoinformatics into "real-life" applications, to step ahead in drug discovery, are of main importance nowadays. Following this aim, and because drug discovery is a complex phenomenon that requires the evaluation of large amounts of chemical data, it could be said that in silico predictions are suitable to detect the biological activity under study.
The algorithm described above, as well as the obtained good results, prompted us to make in silico evaluations of a pool of compounds, isolated and characterized by other research teams, working mainly in tyrosinase inhibitor research based on the trial-and-error method.
One series of compounds (dicoumarins) was selected as tyrosinase inhibitors, showing a good agreement between the in silico predictions and in vitro assays. The values of ΔP% for this subset are depicted in Table 4 . Herein, it is important to highlight that the majority of compounds showed more potent inhibitory activity against the mushroom tyrosinase enzyme than the reference compound, Kojic acid (IC 50 = 16.67 μM), and that compounds DC06, DC10, DC13, DC17, DC19, and DC20 exhibited more potent activity than L-mimosine (IC 50 = 3.68 μM), a highly potent reference drug. The molecular structures of the dicoumarins used in this study are shown in Table 5 .
These results show an experimental example of QSAR application for the development of drug discovery. In addition, it could be effective with further design and optimization of this type of inhibitor lead compound, as a way to improve the activity against the enzyme from the selection of hits, followed by the elucidation of the behavior in the pharmacological and toxicological assays.
LDA model's applicability domain of QSAR data set: the reliability of the predictions in test and novel dicoumarin series
A crucial problem in chemometric and QSAR studies is the definition of the applicability domain (AD) of a classification or regression model. "Not even a robust, significant, and validated QSAR model can be expected to reliably predict the modelled property for the entire universe of chemicals. In fact, only the predictions for chemicals falling within this domain can be considered reliable and not model extrapolations." 32 The AD is a It is generally acknowledged that QSARs are valid only within the same domain for which they were developed. In fact, even if the models are developed from the same chemicals, the AD for new chemicals can differ from model to model, depending on the specific descriptors. However, model validation is sometimes neglected, and the application domain is not always well defined. 34 The purpose of this section is to outline how validation and domain definition determine when it is correct to use the model. The aim of the present work was to develop models for predicting tyrosinase inhibitory activity at early stages of drug discovery and development. In this way, several classes of compounds were used to construct the different LDA-QSAR models. Consequently, one may not extrapolate the use of these models to other kinds of compounds that fall outside the domain of applicability, making uncertain predictions in conditions very different from those fixed to derive the model. 35 It is important to note that in multiple predictor models, simple single-variable range checks are not sufficient to verify the AD. At present, there are several approaches to evaluate the AD of QSAR models. For RLM, the multiple predictor problems with normally distributed data, the distance-based measures, such as leverage, are used most. Through the leverage approach, 36 it is possible to verify whether a new chemical will lie within the structural model domain. The leverage h 36 of a compound measures its influence on the model. That is, leverage used as a quantitative measure of the model AD is suitable for evaluating the degree of extrapolation, which represents a sort of compound "distance" from the model experimental space. Leverage values can be calculated for both training and new compounds. In the former case, they are useful for finding training compounds that influence model parameters to a marked extent, resulting in an unstable model. In the latter case, they are useful for checking the applicability domain of the model. 32, 33 The warning leverage, h*, is a critical value or cut-off to consider the prediction made for the model for a specific compound in the data set. The leverage h* can be defined as 3 × p′/n, where n is the number of training chemicals and p′ is the number of model parameters plus 1. 32, 33 Prediction should be considered unreliable for compounds of high leverage value (h > h*). A leverage greater than the warning leverage h* means that the compound predicted response can be extrapolated from the model and, therefore, the predicted value must be used with great care. Only predicted data for chemicals belonging to the chemical domain of the training set should be proposed. However, this fact can be seen when 2 points of view are taken into consideration for the set of evaluated compounds. For example, when the leverage value of a compound is lower than the critical value, the probability of accordance between the predicted and actual values is as high as the one for the training set of chemicals (good leverage). Conversely, a high-leverage chemical in the test set is structurally distant from the training chemicals (bad leverage); thus, it can be considered outside the AD of the model. In our case, to visualize the AD of an LDA-based QSAR model, we employed a William plot using standardized residuals (first and second ordinates) and leverages (Hat diagonal: abscissa). The h values defined the domain of applicability of the model as a squared area within ±3 or band for residuals, a cut-off value for accepting predictions, because points that lie inside this value of standardized residuals from the mean cover 99% of normally distributed data. Besides, a leverage threshold of h = 0.05649 for tyrosinase inhibitory activity (equation 8) was calculated as the critical leverage value. This William plot can be used for an immediate and simple graphical detection of both the response outliers (i.e., compounds standardized residuals greater than 3 standard deviation units, >3s) and structurally influential chemicals in a model (h > h*). For instance, Figure 4 shows the plot of Equation 8 (for describing tyrosinase activity) as an example. As can be noted in Figure 4 , almost all used compounds lie within this window. Only some chemicals (19 in total) out of 478 compounds in the training set had leverage higher than the threshold but showed standardized residuals within the limits. Furthermore, 2 compounds were wrongly predicted (>3s), and 1 was completely outside the AD of the model, as defined by the Hat vertical line (high h leverage value), finally resulting in 2 outlier chemicals. This result represents an outlier prediction (high leverage value or standardized residual >3s) by every 23 compounds of the total training data set, a value similar to other works reported in the literature. 37, 38 In the case of the test set, depicted in Figure 4 , only 4 compounds fall outside of the applicability domain of this model, which ensures great reliability for the prediction of these kinds of chemicals used in the test set.
Finally, another William plot ( Fig. 5) , with the training set and dicoumarin series discovered as a novel tyrosinase inhibitor compound, was carried out. In this case, all dicoumarins fall within the applicability domain of the model, and thus the predictions are reliable. This proves the good assessment for the classification of these dicoumarins as novel tyrosinase inhibitor compounds. Therefore, this model can be used with high accuracy for the prediction of new compounds in this applicability domain. 35, 36 
CONCLUSIONS
The development of a new drug is a lengthy and complex process. The identification of an appropriate lead molecule is the most critical component of this phase. Over the past few decades, a primary source for novel leads has been the HTS of compound libraries, generally consisting of hundreds of thousands of compounds. The advent of virtual screening (ligandor structure-based) methods to identify a reduced number of molecules with increased potential for bioactivity to be experimentally evaluated has emerged both as a complementary and alternative method to HTS. 39 The molecular structures of these chemicals are shown in Table 5 .
ΔP% = [P(Active) -P(Inactive)]
× 100 as well as canonical scores of each compound in this set: classification of each compound using the obtained models with 2D atom-and bond-based TOMOCOMD-CARDD indices.
a. IC 50 s are the 50% inhibitory concentrations against the mushroom tyrosinase enzyme. Taking into account that QSAR has been applied extensively in recent years to find predictive models for the activity of bioactive agents, as well as that research in many biological activities has been based on traditional trial-and-error methods, we have performed a QSAR study to discriminate tyrosinase inhibitor compounds from inactive ones. The enzyme tyrosinase (EC 1.14.18.1) is widely distributed in the phylogenetic scale and is related to some skin diseases such as melanogenesis disorders and hyperpigmentation. Therefore, it is the target selected for the discovery of new tyrosinase inhibitors because of its broad applications in pharmaceutical, food, and cosmetic industries. Moreover, a data set of active chemical compounds with antityrosinase activity was collected from the literature and could be considered a helpful tool for scientists in this field.
The main idea on the integration of emerging QSAR research strategies is to identify new approaches, as well as to decide which molecular structures to synthesize and ultimately pursue in the drug discovery setting. The impact on decreasing the likelihood of entering the lead drug discovery processes is one topic to be assessed. Therefore, here we have shown how the combination of validated QSAR-modeling and LBVS could be used successfully as innovative technologies, to ensure high expected hit rates in the discovery of new bioactive compounds. In this way, a pool of compounds was subjected to in silico screening and was identified with antityrosinase activity. Later, in vitro experiments corroborated the reliability of the classification functions developed with the TOMOCOMD-CARDD descriptors and the LDA statistical techniques. Biosilico identification of the dicoumarins subset, in the current proposed approach (LBVS), could be considered a suitable alternative for the selection/identification of novel drug-like tyrosinase inhibitors, which may be used to prevent or treat pigmentation disorders if we take into consideration that "chemoinformatics is the combination of chemical synthesis, biological screening and data analysis to guide drug discovery and development." 40
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